Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Perou

Showing results (391-400 of 476) with videos related to

Pageof 48
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2009
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresChad J Creighton, Xiaoxian Li, Melissa Landis, et al.
JAMA Oncology|April 27, 2023
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and PertuzumabAdrienne G Waks, Esther R Ogayo, Laia Paré, et al.
NPJ Breast Cancer|July 20, 2017
DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome AtlasMelissa A Troester, Katherine A Hoadley, Monica D'Arcy, et al.
Cell Reports|October 18, 2018
Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the BreastYeji An, Jessica R Adams, Daniel P Hollern, et al.
ESMO Open|January 18, 2025
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancersF Lynce, O Martínez-Sáez, B Walbaum, et al.
Ebiomedicine|March 6, 2024
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studiesBenedetta Conte, Fara Brasó-Maristany, Adela Rodríguez Hernández, et al.
The Oncologist|April 25, 2015
Defining breast cancer intrinsic subtypes by quantitative receptor expressionMaggie C U Cheang, Miguel Martin, Torsten O Nielsen, et al.
Journal of the National Cancer Institute|December 28, 2022
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, et al.
Breast Cancer Research and Treatment|July 9, 2014
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastasesCarey Anders, Allison M Deal, Vandana Abramson, et al.
Journal of the National Cancer Institute|December 11, 2014
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studiesMatthew P Goetz, James X Sun, Vera J Suman, et al.
Pageof 48

Showing results (391-400 of 476) with videos related to

Sort By:
Pageof 48
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2009
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating featuresChad J Creighton, Xiaoxian Li, Melissa Landis, et al.
JAMA Oncology|April 27, 2023
Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and PertuzumabAdrienne G Waks, Esther R Ogayo, Laia Paré, et al.
NPJ Breast Cancer|July 20, 2017
DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome AtlasMelissa A Troester, Katherine A Hoadley, Monica D'Arcy, et al.
Cell Reports|October 18, 2018
Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the BreastYeji An, Jessica R Adams, Daniel P Hollern, et al.
ESMO Open|January 18, 2025
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancersF Lynce, O Martínez-Sáez, B Walbaum, et al.
Ebiomedicine|March 6, 2024
A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studiesBenedetta Conte, Fara Brasó-Maristany, Adela Rodríguez Hernández, et al.
The Oncologist|April 25, 2015
Defining breast cancer intrinsic subtypes by quantitative receptor expressionMaggie C U Cheang, Miguel Martin, Torsten O Nielsen, et al.
Journal of the National Cancer Institute|December 28, 2022
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1Fara Brasó-Maristany, Gaia Griguolo, Nuria Chic, et al.
Breast Cancer Research and Treatment|July 9, 2014
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastasesCarey Anders, Allison M Deal, Vandana Abramson, et al.
Journal of the National Cancer Institute|December 11, 2014
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studiesMatthew P Goetz, James X Sun, Vera J Suman, et al.
Pageof 48